Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4640 | Venetoclax Wiki | 0.58 |
drug2055 | Ibrutinib Wiki | 0.50 |
Navigate: Correlations HPO
There is one clinical trial.
A study to evaluate the safety and efficacy of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows: Stage 1: Enroll 14 participants with relapsed or refractory (R/R) T-PLL and move to Stage 2 if 4 or more participants meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment. Stage 2: Enroll up to an additional 23 participants.
Description: ORR is defined as the percentage of participants achieving complete remission (CR), CR with incomplete bone marrow recovery (CRi), or partial response (PR) as their best response (per investigator assessment).
Measure: Overall Response Rate (ORR) Time: Up to approximately 2 yearsDescription: PFS is defined as the time from the date of first dose of any study drug to the date of earliest disease progression or death.
Measure: Progression-Free Survival (PFS) Time: Up to approximately 2 yearsDescription: DOR defined for participants who achieve a best overall response of CR, CRi, or PR, as the time from the date of first response (CR, CRi, or PR) to the earliest date of disease progression or death.
Measure: Duration of Response (DOR) Time: Up to approximately 2 yearsDescription: TPP is defined as the time from the date of the participant's first dose of any study drug to the date of earliest disease progression.
Measure: Time to Progression (TTP) Time: Up to approximately 2 yearsDescription: EFS is defined as time from participant's first dose of any study drug to the date of earliest disease progression, death, or start of a new anti-T-PLL therapy.
Measure: Event-free Survival (EFS) Time: Up to approximately 2 yearsDescription: DCR defined as the percentage of participants achieving CR, CRi, PR, or stable disease as best overall response.
Measure: Disease Control Rate (DCR) Time: Up to approximately 2 yearsDescription: OS is defined as the time from the date of the participant's first dose of any study drug to death from any cause.
Measure: Overall Survival (OS) Rate Time: Up to approximately 2 yearsDescription: Number of eligible participants reaching autologous or allogeneic transplantation.
Measure: Number of Eligible Participants Reaching Autologous or Allogeneic Transplantation Time: Up to approximately 2 yearsDescription: AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Measure: Number of Participants with Adverse Events (AE) Time: Up to approximately 2 yearsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports